Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
VIP Vasoactive Intestinal Peptide is a neuropeptide with regulatory effects across multiple systems
The phospholipid carriers used in liposomal glutathione supplements are similar to cellular membranes, allowing for seamless integration and transport across cellular barriers
This medication is provided under the supervision of a licensed prescriber
